Charles Newton
Director of Finance/CFO at LYELL IMMUNOPHARMA, INC.
Net worth: 90 418 $ as of 2024-04-29
Profile
Charles Newton's current job(s) include serving as an Independent Director at Carmot Therapeutics, Inc. since 2023, at Coherus BioSciences, Inc. since 2022, at 2seventy Bio, Inc. since 2024, and as the Chief Financial Officer at Lyell Immunopharma, Inc. since 2021.
Formerly, Mr. Newton worked as a Managing Director at Morgan Stanley from 1996 to 2010, at BofA Securities, Inc., and as a Managing Director at Credit Suisse Group AG from 2010 to 2015.
Mr. Newton completed his undergraduate degree at Miami University and holds an MBA from the Tuck School of Business at Dartmouth.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0.03% | 2024-03-19 | 16,600 ( 0.03% ) | 71 214 $ | 2024-04-29 |
LYELL IMMUNOPHARMA, INC.
0.00% | 2024-03-30 | 8,729 ( 0.00% ) | 19 204 $ | 2024-04-29 |
| 2024-04-08 | 0 ( -.--% ) | - $ | 2024-04-29 |
Charles Newton active positions
| Companies | Position | Start |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Director of Finance/CFO | 2021-01-31 |
| COHERUS BIOSCIENCES, INC. | Director/Board Member | 2022-05-04 |
| 2SEVENTY BIO, INC. | Director/Board Member | 2024-03-19 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Director/Board Member | 2023-07-18 |
Former positions of Charles Newton
| Companies | Position | End |
|---|---|---|
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Chief Executive Officer | 2015-10-31 |
| MORGAN STANLEY | Corporate Officer/Principal | 2010-08-31 |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - |
Training of Charles Newton
| Tuck School of Business at Dartmouth | Masters Business Admin |
| Miami University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| MORGAN STANLEY | Finance |
| 2SEVENTY BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Charles Newton
